No Data
Individual Investors Among Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Largest Stockholders and Were Hit After Last Week's 4.8% Price Drop
Shanghai Yizhong (688091.SH): The core product paclitaxel polymer micelle for injection has been included in the national medical insurance list.
On November 28, 格隆汇 reported that shanghai Yizhong (688091.SH) announced that the National Healthcare Security Administration released the notification on "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)" on November 28, 2024 (Healthcare Security [2024] No. 33). The company's core product, paclitaxel polymer micelles for injection, has been included in the part of the National Medical Insurance Catalog Category B management, with the scope of medical insurance payment being: "Limited to combined with platinum-based drugs for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, unresectable locally advanced or metastatic non-liver cancer."
Shanghai Yizhong (688091.SH): Cumulatively repurchased 0.5179% of shares.
On November 4, GeLongHui reported that Shanghai Yizhong (688091.SH) announced that as of October 31, 2024, the company repurchased a total of 1,065,694 shares of the company through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 0.5179% of the company's current total share capital of 205,759,840 shares. The highest price for the repurchase transaction was 29.56 yuan per share, the lowest price was 25.54 yuan per share, and the total amount paid was RMB 27,935,885.49 (excluding transaction fees).
Shanghai Yizhong: Report of Shanghai Yizhong Pharmaceutical Co., Ltd. for the third quarter of 2024
Shanghai Yizhong Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
shanghai Yizhong (688091.SH) released its performance for the first three quarters, with a net income of 34.67 million yuan, a 73.46% year-on-year decrease.
Shanghai Yizhong (688091.SH) disclosed its third quarter report for 2024, achieving operating income for the first three quarters...
No Data
